MedTrace Logo

Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.

NCT05031481 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of different doses of Venus association in the treatment of vulvovaginal candidiasis.

Conditions

  • Vulvovaginal Candidiasis

Interventions

DRUG

Venus 20 + 0,064

Venus vaginal cream 20 + 0,064, single-dose.

DRUG

Venus 20 + 1

Venus vaginal cream 20 + 1, single-dose.

DRUG

Venus 20 + 4

Venus vaginal cream 20 + 4, single-dose.

DRUG

Butoconazole nitrate

Butoconazole nitrate vaginal cream, 100 mg single-dose.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2024-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031481 on ClinicalTrials.gov